XBI

Equity ETFs

Healthcare ETFs Slip After Abbot Lab’s Revenue Miss, Weak Outlook

By Max ChenJanuary 23, 2019

Equity ETFs

Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology

By Max ChenJanuary 7, 2019

Leveraged & Inverse Channel

Biotech ETFs Hoping This Post-Election Trend Doesn’t Repeat

By Brenton GarenNovember 8, 2018

Equity ETFs

Sarepta Therapeutics Helps Biotech ETFs Buck Market Trend

By Max ChenJune 19, 2018

Equity ETFs

6 Top Healthcare ETFs Rally as Trump Vows End to ‘Global Freeloading’

By Max ChenMay 11, 2018

Equity ETFs

Catalysts Abound for Biotech ETFs

By Tom LydonApril 10, 2018

Equity ETFs

Alkermes FDA Refusal: Biotech ETFs Dragged Down

By Max ChenApril 2, 2018

Equity ETFs

Healthcare Dip Could be a Buying Opportunity

By Brenton GarenFebruary 5, 2018

Equity ETFs

Biotech ETFs Pop on Celgene, Juno Deal

By Max ChenJanuary 22, 2018

Equity ETFs

Biotech Slump Could be a Buying Opportunity

By Tom LydonDecember 5, 2017

Equity ETFs

Biotech Decline Could be a Buying Opportunity

By Brenton GarenNovember 16, 2017

Equity ETFs

Why Healthcare Sector is a Great November Play

By Tom LydonOctober 27, 2017

Equity ETFs

Hot Biotech Stocks, ETFs Can Keep Surging

By Tom LydonOctober 10, 2017

Equity ETFs

Bullish Biotech Bets After Positive Attention

By Tom LydonOctober 5, 2017

Equity ETFs

A Good Time to Own Biotech ETFs

By Tom LydonOctober 2, 2017

Equity ETFs

Evaluating the Biotech ETF Rally

By Tom LydonSeptember 28, 2017

Equity ETFs

Biotech ETF Investing is Hot, Can Get Hotter

By Tom LydonSeptember 8, 2017

Equity ETFs

Biotech ETFs Remain Bell of the Ball

By Brenton GarenSeptember 1, 2017